Waldenström's macroglobulinemia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
 
__NOTOC__
{{CMG}}{{AE}}{{MGS}}
{{Waldenström's macroglobulinemia}}
{{Waldenström's macroglobulinemia}}


Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including:
Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including:


*Chronic lymphocytic leukemia/small lymphocytic lymphoma:  
*[[Chronic lymphocytic leukemia]]/[[small lymphocytic lymphoma]]:  
::*Always express CD5, usually CD23 positive<ref name="UTD">Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link&sectionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015</ref>
::*Always express CD5, usually CD23 positive<ref name="UTD">Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link&sectionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015</ref>


*B-cell prolymphocytic leukemia:  
*[[B-cell prolymphocytic leukemia]]:  
::*Express bright surface IgM, CD20 and other B-cell antigens (CD19, CD22, CD79a, FMC7)<ref name="UTD"></ref>
::*Express bright surface IgM, CD20 and other B-cell antigens (CD19, CD22, CD79a, FMC7)<ref name="UTD"></ref>


*Follicular lymphoma:  
*[[Follicular lymphoma]]:  
::*Express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA<ref name="UTD"></ref>
::*Express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA<ref name="UTD"></ref>
::*Bone marrow infiltration of small, cleaved cells that are usually paratrabecular<ref name="pubM">{{cite journal |vauthors=Sahin I, Leblebjian H, Treon SP, Ghobrial IM |title=Waldenström macroglobulinemia: from biology to treatment |journal=Expert Rev Hematol |volume=7 |issue=1 |pages=157–68 |year=2014 |pmid=24405328 |doi=10.1586/17474086.2014.871494 |url=}}</ref>
::*Bone marrow infiltration of small, cleaved cells that are usually paratrabecular<ref name="pubM">{{cite journal |vauthors=Sahin I, Leblebjian H, Treon SP, Ghobrial IM |title=Waldenström macroglobulinemia: from biology to treatment |journal=Expert Rev Hematol |volume=7 |issue=1 |pages=157–68 |year=2014 |pmid=24405328 |doi=10.1586/17474086.2014.871494 |url=}}</ref>
::*Rearrangement of Bcl-2
::*Rearrangement of Bcl-2


*Multiple myeloma:  
*[[Multiple myeloma]]:  
::*Express CD138, CD38, CD79a, and VS38c and CD56(70%)<ref name="UTD"></ref>
::*Express CD138, CD38, CD79a, and VS38c and CD56(70%)<ref name="UTD"></ref>
::*Presence of Plasmacytic cell infiltration of bone marrow, osteolytic lesions and renal insufficiency<ref name="pubM"></ref>
::*Presence of Plasmacytic cell infiltration of bone marrow, osteolytic lesions and [[renal insufficiency]]<ref name="pubM"></ref>
::*Translocation involving chromosome 11 (t 11;14)  
::*Translocation involving chromosome 11 (t 11;14)  


*Mantle cell lymphoma:
*[[Mantle cell lymphoma]]:
::* Express CD5+ and CD23-, surface IgM and IgD and cyclin D1 in majority of cases<ref name="UTD"></ref>
::* Express CD5+ and CD23-, surface IgM and IgD and cyclin D1 in majority of cases<ref name="UTD"></ref>
::*Infiltration of bone marrow by monomorphous, small lymphoid cells with irregular nuclei<ref name="pubM"></ref>
::*Infiltration of bone marrow by monomorphous, small lymphoid cells with irregular nuclei<ref name="pubM"></ref>
Line 28: Line 29:
::*Infiltrates the bone marrow with a characteristic intertrabecular and intrasinusoidal pattern<ref name="pubM"></ref>
::*Infiltrates the bone marrow with a characteristic intertrabecular and intrasinusoidal pattern<ref name="pubM"></ref>
::*Most common cytogenetic abnormalities are loss of 7q (19%) along with +3q (19%) and +5q (10% )
::*Most common cytogenetic abnormalities are loss of 7q (19%) along with +3q (19%) and +5q (10% )


=References==
=References==

Revision as of 20:01, 12 November 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]

Waldenström's macroglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Waldenström's macroglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Bone Marrow Aspiration and Biopsy

Electrophoresis and Immunofixation

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Waldenström's macroglobulinemia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Waldenström's macroglobulinemia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Waldenström's macroglobulinemia differential diagnosis

CDC on Waldenström's macroglobulinemia differential diagnosis

Waldenström's macroglobulinemia differential diagnosis in the news

Blogs on Waldenström's macroglobulinemia differential diagnosis

Directions to Hospitals Treating Waldenström's macroglobulinemia

Risk calculators and risk factors for Waldenström's macroglobulinemia differential diagnosis

Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including:

  • Always express CD5, usually CD23 positive[1]
  • Express bright surface IgM, CD20 and other B-cell antigens (CD19, CD22, CD79a, FMC7)[1]
  • Express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA[1]
  • Bone marrow infiltration of small, cleaved cells that are usually paratrabecular[2]
  • Rearrangement of Bcl-2
  • Express CD138, CD38, CD79a, and VS38c and CD56(70%)[1]
  • Presence of Plasmacytic cell infiltration of bone marrow, osteolytic lesions and renal insufficiency[2]
  • Translocation involving chromosome 11 (t 11;14)
  • Express CD5+ and CD23-, surface IgM and IgD and cyclin D1 in majority of cases[1]
  • Infiltration of bone marrow by monomorphous, small lymphoid cells with irregular nuclei[2]
  • Marginal zone lymphoma:
  • Expresses B cell markers CD19, CD20, and CD22[1]
  • Infiltrates the bone marrow with a characteristic intertrabecular and intrasinusoidal pattern[2]
  • Most common cytogenetic abnormalities are loss of 7q (19%) along with +3q (19%) and +5q (10% )

References=

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link&sectionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015
  2. 2.0 2.1 2.2 2.3 Sahin I, Leblebjian H, Treon SP, Ghobrial IM (2014). "Waldenström macroglobulinemia: from biology to treatment". Expert Rev Hematol. 7 (1): 157–68. doi:10.1586/17474086.2014.871494. PMID 24405328.

Template:WH Template:WS